NASDAQ:ITRM - Iterum Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.88
  • Forecasted Upside: 313.14 %
  • Number of Analysts: 6
  • Breakdown:
  • 2 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.18
▲ +0.03 (2.61%)
1 month | 3 months | 12 months
Get New Iterum Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ITRM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ITRM

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$4.88
▲ +313.14% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Iterum Therapeutics in the last 3 months. The average price target is $4.88, with a high forecast of $9.00 and a low forecast of $1.50. The average price target represents a 313.14% upside from the last price of $1.18.
Hold
The current consensus among 6 contributing investment analysts is to hold stock in Iterum Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/30/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/29/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
9/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
10/21/2020

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/1/2020SVB LeerinkBoost Price TargetMarket Perform$1.00 ➝ $1.50High
i
8/10/2020Royal Bank of CanadaReiterated RatingHold$2.00Medium
i
Rating by Gregory Renza at Royal Bank of Canada
6/16/2020HC WainwrightDowngradeBuy ➝ NeutralLow
i
Rating by E. Arce at HC Wainwright
6/2/2020SVB LeerinkLower Price TargetMarket Perform$2.00 ➝ $1.00High
i
Rating by Ami Fadia at SVB Leerink LLC
6/2/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$7.00 ➝ $2.00High
i
5/15/2020HC WainwrightReiterated RatingBuy$9.00Medium
i
5/14/2020Needham & Company LLCReiterated RatingBuy$7.00High
i
5/14/2020Royal Bank of CanadaReiterated RatingOutperform ➝ Market Perform$8.00Medium
i
3/13/2020Needham & Company LLCReiterated RatingBuyLow
i
1/21/2020G.ResearchDowngradeBuy ➝ SellHigh
i
Rating by K. Kedra at G.Research, Llc
1/21/2020GabelliDowngradeBuy ➝ SellHigh
i
12/11/2019Royal Bank of CanadaLower Price TargetPositive ➝ Outperform$14.00 ➝ $10.00High
i
12/11/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$4.00High
i
11/14/2019G.ResearchReiterated RatingBuyHigh
i
Rating by K. Kedra at G.Research, Llc
8/15/2019HC WainwrightReiterated RatingBuy$17.00Medium
i
Rating by E. Arce at HC Wainwright
6/21/2019HC WainwrightInitiated CoverageBuy ➝ Buy$17.00High
i
Rating by E. Arce at HC Wainwright
5/15/2019Royal Bank of CanadaLower Price TargetOutperform$17.00Low
i
3/25/2019Needham & Company LLCReiterated RatingBuy$20.00Low
i
Rating by Alan Carr at Needham & Company LLC
11/14/2018Needham & Company LLCSet Price TargetBuy$20.00High
i
Rating by Alan Carr at Needham & Company LLC
10/22/2018GabelliReiterated RatingBuyLow
i
Rating by K. Kedra at Gabelli
8/14/2018Needham & Company LLCSet Price TargetBuy$20.00High
i
Rating by Alan Carr at Needham & Company LLC
6/19/2018Royal Bank of CanadaInitiated CoverageOutperform$24.00High
i
6/19/2018Needham & Company LLCInitiated CoverageBuy$20.00High
i
6/19/2018SVB LeerinkInitiated CoverageOutperform$18.00High
i
Rating by A. Fadia at SVB Leerink LLC
6/19/2018GuggenheimInitiated CoverageBuy$21.00High
i
(Data available from 10/21/2015 forward)
Iterum Therapeutics logo
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $1.18
$0.96
$1.19

50 Day Range

MA: $0.78
$0.58
$1.20

52 Week Range

Now: $1.18
$0.51
$7.19

Volume

3,914,992 shs

Average Volume

1,804,197 shs

Market Capitalization

$25.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7